Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion
NASDAQ:VCNX

Vaccinex Q2 2024 Earnings Results & Report

Vaccinex logo
$0.70 0.00 (0.00%)
As of 10/20/2026 02:14 PM Eastern

Vaccinex reported Q2 2024 earnings on August 14, 2024. The company reported EPS of -$3.10, while revenue was $0.23 million.

Research:Profile

Earnings Announcement Details

Quarter
Q2 2024
Report Date

Vaccinex EPS Results

Actual EPS
-$3.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Vaccinex Revenue Results

Actual Revenue
$0.23 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Vaccinex's next earnings date is estimated for Monday, November 16, 2026, based on past reporting schedules.

Conference Call Resources

Vaccinex Q2 2024 Earnings FAQ

Vaccinex (NASDAQ:VCNX) reported earnings of -$3.10 per share for Q2 2024. The report was announced on Wednesday, August 14, 2024.

Vaccinex reported revenue of $0.23 million for Q2 2024.

Vaccinex's next earnings date is estimated for Monday, November 16, 2026. MarketBeat tracks confirmed and estimated earnings dates for Vaccinex on the company's earnings history page.

Vaccinex Earnings Headlines

SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study
October 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376451/34858/en/sema4d-blockade-reshapes-the-tumor-immune-environment-in-neoadjuvant-melanoma-study.html
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324070/34858/en/vaccinex-to-report-new-biomarker-data-and-plans-for-phase-2b-clinical-trial-of-pepinemab-in-ad-at-the-alzheimer-s-association-international-conference-in-london-on-july-13-2026.html
Buffett's Final Warning: "The Dollar Is Going to Hell"
On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.tc pixel
October 21 at 1:00 AM  |  Decentralized Masters (Ad)
Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025
April 29, 2026  |  quiverquant.comQ
Vaccinex Reports 2025 Annual Financial Results
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284388/34858/en/vaccinex-reports-2025-annual-financial-results.html
Vaccinex Inc.
April 10, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/vcnx/company-people
See More Vaccinex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vaccinex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaccinex and other key companies, straight to your email.

About Vaccinex

Vaccinex (NASDAQ:VCNX) is a clinical-stage biotechnology company headquartered in Rochester, New York. The company develops antibody-based therapies for serious diseases, with a focus on conditions involving neurodegeneration, cancer and immune-system dysfunction.

Vaccinex’s lead product candidate is pepinemab, also known as VX15/2503, a humanized monoclonal antibody designed to block Semaphorin 4D (SEMA4D). The company has evaluated pepinemab in clinical studies for Huntington’s disease and Alzheimer’s disease, as well as in oncology programs, including research investigating its potential use in combination with other cancer treatments.

Vaccinex also maintains antibody-discovery and development capabilities intended to support the creation of additional therapeutic candidates and potential collaborations. The company’s programs are developed through clinical research conducted in the United States and in collaboration with academic and industry partners. Vaccinex was co-founded by Maurice Zauderer, Ph.D., who has served as its president and chief executive officer.

View Vaccinex Profile
Earnings Tools